Navigation Links
Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimer's DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
Date:8/16/2011

SAN DIEGO, Aug. 16, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced today that a subgroup analysis of patients receiving concomitant systemic antibiotics in two Phase 3 clinical trials exploring the use of DIFICID™ (fidaxomicin) tablets in the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD) was published online in the September 1 issue of Clinical Infectious Diseases (CID). The analysis found that in the presence of concomitant systemic antibiotic therapy, which is the use of antibiotics to treat concurrent infections, DIFICID achieved a significantly higher initial clinical cure rate, and higher rate of global cure, compared to oral vancomycin. In the article, approximately 28% of patients in the Phase 3 clinical trials required antibiotic treatment for concurrent infections, primarily lung and urinary tract, and these treatments had an adverse impact on the efficacy of both CDAD therapies.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Patients with CDAD who received DIFICID while taking concomitant antibiotics demonstrated a significantly higher clinical cure rate of CDAD than patients who received oral vancomycin and concomitant antibiotics (90.0% clinical cure rate vs. 79.4%, respectively; p=0.04).Regardless of concomitant antibiotic use, DIFICID was also statistically superior to oral vancomycin in global cure rate. Global cure is defined as clinical cure with no recurrence through the end of study visit 26 to 30 days after completion of CDAD treatment.

"To date, there has been little research demonstrating the impact of concomitant antibiotic use in patients being treated for CDAD," said Dr. Kathleen Mullane, Associate Professor of Medicine at The University of Chicago Department of M
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... N.Y. , Aug. 22, 2014  Mark ... tomography (CT) imaging facility, is using the online ... and even 5D imaging to researchers and would-be ... launched, asks "What would YOU do if you ... possibility to researchers and explorers everywhere, from elementary ...
(Date:8/22/2014)... , Aug. 22, 2014 /PRNewswire/ - SQI ... that develops and commercializes proprietary technologies and products ... has entered into a Master Service Agreement to ... DNA-based pathogen detection assays. During the initial phase ... deliver an automated working prototype of one of ...
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic cancers and women,s health, has appointed Holly ... Managed Markets. Ms. Bauzon has a proven ... payer coverage for laboratory services companies. She has more ... PerkinElmer, Inc., where she held the position of Director, ...
Breaking Medicine Technology:Cornell's X-ray Imaging Lab Director Uses Kickstarter Campaign to "Democratize" Advanced 3D Imaging 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 2SQI Diagnostics Contracted to Automate Pathogen Detection Assays 3Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2
... May 2, 2011 eResearchTechnology, Inc. (ERT), (Nasdaq: ... of  services and customizable medical devices to biopharmaceutical ... cardiac safety and respiratory efficacy services in drug ... ended March 31, 2011.  Unless otherwise noted, all ...
... 2, 2011 The U.S. Food and Drug Administration ... exercise, to improve blood glucose control in adults with ... People with Type 2 diabetes do not ... regulates the amount of glucose in the blood. Over ...
Cached Medicine Technology:ERT Reports First Quarter 2011 Operating Results 2ERT Reports First Quarter 2011 Operating Results 3ERT Reports First Quarter 2011 Operating Results 4ERT Reports First Quarter 2011 Operating Results 5ERT Reports First Quarter 2011 Operating Results 6ERT Reports First Quarter 2011 Operating Results 7ERT Reports First Quarter 2011 Operating Results 8ERT Reports First Quarter 2011 Operating Results 9ERT Reports First Quarter 2011 Operating Results 10ERT Reports First Quarter 2011 Operating Results 11FDA Approves New Treatment for Type 2 Diabetes 2
(Date:8/22/2014)... Today, Zane Benefits, the #1 Online ... Health Plans. , According to Zane Benefits, employers are ... lower the cost of healthcare without reducing coverage for ... however, can be confusing. , The new guide contains ... main types of ABHPs. It also explains the ...
(Date:8/22/2014)... 2014 This report studies the ... Handling Systems), Consumables (Tubes), Kits (Isolation, Purification), By ... - Global Forecast to 2018" This market was ... poised to grow at a CAGR of 5.9% ... by 2018. , Browse 98 market data Tables ...
(Date:8/22/2014)... (PRWEB) August 23, 2014 Recently, iFitDress.com, ... its new collection of discounted wedding gowns . ... announced that all these new products are provided with ... are very happy to unveil the new wedding gowns. ... special occasion gowns for ladies to choose from. What’s ...
(Date:8/22/2014)... -- Many Americans know little about how Ebola is transmitted ... in the United States, a new survey shows. About ... will be a major Ebola outbreak in the United States, ... member will get sick with the deadly virus in the ... Health poll. However, those opinions don,t match reality, the ...
(Date:8/22/2014)... Mi40x , the latest guide from ... people how they can use a simple 4-minute trick to ... of weeks has caught the attention of Shane Michaels, prompting ... the most well-known bodybuilders in the industry, and if he ... that in itself is a testament to how effective this ...
Breaking Medicine News(10 mins):Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
... at Ross University School of Medicine,s 2009 graduation ceremony at The Theater ... ... 2009 -- Ross University is pleased to announce that Richard H. Carmona, ... Theater at Madison Square Garden on Friday, June 5. , , , ...
... Bring Dreams, a program created by dekoposh, Inc. will ... for Mattel Children,s Hospital UCLA during the highly anticipated ... Baby & Tween Celebration LA and Jeans Bring ... charityfolks.com, and live during Baby & Tween Celebration LA ...
... with biphosphonates could prevent radiation-induced leukemia, according to data ... Annual Meeting 2009. , Alexandra Miller, Ph.D., a ... said her research is designed to help military and ... exposed to risky levels of radiation than the general ...
... San Diego and the Moores UCSD Cancer Center have evidence ... an often difficult-to-treat form of leukemia. They found that high ... indicator that chronic lymphocytic leukemia (CLL) the most common ... need of immediate treatment. , The researchers, led by ...
... nearly 9 times the risk, scientists say , , SUNDAY, April ... might spot smokers at highest risk for lung cancer, scientists ... and it may be years before such a test becomes ... give added motivation to smokers who can,t find other reasons ...
... Data Show Fleximer(R) Extends Exposure to Conjugated Drug ... cancer therapeutics company, today announced positive results of ... in two posters at the 2009 Annual Meeting ... in Denver. The studies showed that XMT-1107, ...
Cached Medicine News:Health News:Former U.S. Surgeon General to Speak at Ross University School of Medicine's 2009 Graduation 2Health News:Celebrity Signed Jeans Live at Auction During Baby & Tween Celebration LA 2Health News:New biomarker may predict leukemia aggressiveness 2Health News:Urine Test Could Gauge Smokers' Lung Cancer Risk 2Health News:Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting 2Health News:Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting 3
Injection Cannula, Angled; 20g (0.90) x 1" (25mm); Tip Extension: 5mm, 30g (0.30); Angled at 45°, 2.5mm from Tip....
...
Lacrimal Cannula, Curved - Open End, 21gSize: 21g x 1-1/2"....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: